Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 9/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11825969 | 0.76 | OPRL1 (0.51) | HTR2COPRL1KCNH2DRD4OPRM1 | |
| SCHEMBL13450177 | 0.76 | MEN1 (0.67) | OPRL1DRD4OPRM1DRD2MEN1 | |
| SCHEMBL3436371 | 0.76 | SLC18A3 (0.61) | HTR2COPRL1KCNH2DRD4OPRM1 | |
| SCHEMBL10276962 | 0.76 | HTR2C (0.47) | HTR2COPRL1KCNH2DRD4DRD2 | |
| SCHEMBL13999713 | 0.75 | HTR2C (0.47) | HTR2COPRL1KCNH2DRD4OPRM1 | |
| SCHEMBL3554720 | 0.75 | DRD4 (0.52) | HTR2COPRL1KCNH2DRD4OPRM1 | |
| SCHEMBL13085385 | 0.74 | HTR2C (0.58) | HTR2COPRL1KCNH2DRD4 | |
| SCHEMBL1225741 | 0.73 | HTR2C (0.72) | HTR2COPRL1KCNH2ACHE | |
| SCHEMBL21139621 | 0.73 | HTR2C (0.56) | HTR2COPRL1KCNH2DRD4 | |
| SCHEMBL13408187 | 0.73 | HTR2C (0.56) | HTR2COPRL1KCNH2DRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | HTR2C 1146/4885OPRL1 51/4885KCNH2 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.